Immunitybio Inc (IBRX)
Healthcare
Biotechnology
7.20 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Immunitybio Inc (IBRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -75 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80 | -87 | -115 | -107 | -100 | -99 | -85 | -86 | -80 | -69 | -70 | -75 | -294 | |
| 4.7 | 16 | 4.6 | 4.6 | 4.4 | 4.4 | 4.1 | 3.8 | 3.9 | 4.0 | 3.9 | 4.4 | 16 | |
| 11 | 14 | 13 | 8.3 | 9.6 | 7.5 | 9.0 | 9.5 | 9.6 | 8.9 | 8.7 | 8.2 | 35 | |
| 33 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 9.1 | -4.3 | -26 | -3.9 | 5.4 | -10 | -11 | -22 | -5.6 | -12 | -14 | -0.5 | -33 | |
| 8.5 | 5.7 | 8.0 | 1.3 | 0.7 | 2.8 | 2.1 | 1.1 | 1.1 | 0.8 | 1.3 | 1.8 | 4.9 | |
| -8.6 | -16 | 2.2 | -36 | -51 | 65 | 9.8 | 4.1 | -16 | -181 | 44 | -32 | -186 | |
| 0.1 | 1.5 | – | 0.0 | – | – | – | 0.0 | – | – | – | – | – | |
| -0.1 | -1.5 | -1.6 | -3.9 | -3.9 | 3.9 | – | – | – | – | – | – | – | |
| 30 | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.9 | 0.0 | 2.9 | |
| 43 | 238 | 201 | 10 | 149 | 16 | 107 | -1.0 | 173 | 174 | 55 | 224 | 625 | |
| -45 | 134 | 87 | -132 | -2.9 | -18 | 32 | -83 | 77 | -77 | 28 | 117 | 145 | |
| -88 | -93 | -123 | -108 | -101 | -102 | -87 | -87 | -81 | -70 | -72 | -77 | -299 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.